Nkarta, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $77.00K, a 51.27% decline year-over-year.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $158.00K, a 57.75% decline year-over-year.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $374.00K.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $4.75M.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $141.00K, a 58.89% decline from fiscal 2024.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $343.00K, a 35.28% decline from fiscal 2023.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $530.00K, a 19.10% increase from fiscal 2022.
- Nkarta, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $445.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $141.00K 10-K · filed 2026-03-25 | |
| 2025-06-30 | $77.00K 10-Q · filed 2025-11-10 | |
| 2024-12-31 | $343.00K 10-K · filed 2026-03-25 | |
| 2024-06-30 | $158.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $530.00K 10-K · filed 2025-03-26 | |
| 2023-06-30 | $374.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $4.75M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $445.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |